Richard E. Pratley, MD
Medical Director at the AdventHealth Diabetes Institute, Senior Investigator, Diabetes Program Lead at the Translational Research Institute
Translational Research, Infectious Disease
Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.
Indirect treatment comparisons: Choosing the right tool for the job.
Diabetes, obesity & metabolism
Y Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
BMJ OPEN DIABETES RESEARCH & CARE
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 d
Contemporary clinical trials
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes.
Diabetes, obesity & metabolism
The Ile191Val Variant of the TAS1R2 Subunit of Sweet Taste Receptors Is Associated With Reduced HbA(1c) in a Human Cohort With Variable Levels of Glucose Homeostasis
FRONTIERS IN NUTRITION
Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes
Diabetes technology & therapeutics
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
DIABETES OBESITY & METABOLISM
Education & Training
Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn
University of Michigan, Ann Arbor, MI
University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD
American Board of Internal Medicine